RTX stock points to 2027 growth as backlog supports execution

Published on 11/11/2026 at 16:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RTX stock enters a fresh execution phase after management reaffirmed its 2026 outlook. Management expects sales, profit and free cash flow to grow in 2027.

RTX sets a 2027 execution test

Chief Financial Officer Neil Mitchill reaffirmed RTX's full-year operating outlook at the Baird conference.
Management expects all three segments to deliver operating-profit growth and margin expansion in 2027.
Formal 2027 guidance is scheduled for the January earnings call.

RTX Corporation, US75513E1010, Illustration mit AI erstellt.

RTX Corporation is moving into a new execution phase after Chief Financial Officer Neil Mitchill reaffirmed the company's 2026 outlook at the Baird 2026 Global Industrial Conference on Tuesday, November 10. The update adds a forward-looking 2027 perspective to the operating targets already covered in the previous report.

RTX stock traded at 179.50 euros on Lang & Schwarz at 16:43 CET on Wednesday, November 11, 2026, 5.06 percent above the 170.85-euro quote cited in the company's November 9 report. This report-to-report comparison is separate from the daily Xetra comparison.

Management raises the 2027 bar

According to MarketBeat, Mitchill said RTX still expects 2026 sales of 97.0 billion to 97.5 billion US dollars, adjusted earnings per share of 7.65 to 7.75 US dollars and free cash flow of 9.0 billion to 9.2 billion US dollars. The CFO tied delivery execution and customer collections to the year-end performance.

For 2027, management expects sales, operating profit and free cash flow to increase across the business. All three major segments are expected to deliver operating-profit growth and margin expansion, although some benefits from 2026 will not recur. Formal 2027 guidance is planned for the January earnings call.

Backlog supports, execution decides

The order book remains the central support for the outlook, while production capacity, working capital and cash conversion are the main execution tests. Raytheon has more than 80 percent of expected 2027 sales in backlog, with at least 85 percent of that amount fully funded, according to Mitchill.

Defense demand is being reinforced by munitions framework agreements that could represent up to 70 billion US dollars in contracts. Commercial aftermarket demand also remains firm, with geared-turbofan shop visits booked through 2027. Investors will therefore focus on conversion of the backlog into deliveries and cash rather than on the order-book figure alone.